PPARγ in human and mouse physiology

被引:186
作者
Heikkinen, Sami
Auwerx, Johan [1 ]
Argmann, Carmen A.
机构
[1] Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol Cell, F-67404 Illkirch Graffenstaden, France
[2] Univ Kuopo, AI Virtanen Inst Mol Sci, FI-70211 Kuopio, Finland
[3] Inst Clin Souris, F-67404 Illkirch Graffenstaden, France
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2007年 / 1771卷 / 08期
关键词
PPAR-gamma; mouse models; human genetic variants; longevity; bone homeostasis; metabolism;
D O I
10.1016/j.bbalip.2007.03.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The peroxisome proliferator activated receptor gamma (PPAR gamma) is a member in the nuclear receptor superfamily which mediates part of the regulatory effects of dietary fatty acids on gene expression. As PPAR gamma also coordinates adipocyte differentiation, it is an important component in storing the excess nutritional energy as fat. Our genes have evolved into maximizing energy storage, and PPAR gamma has a central role in the mismatch between our genes and our affluent western society which results in a broad range of metabolic disturbances, collectively known as the metabolic syndrome. A flurry of human and mouse studies has shed new light on the mechanisms how the commonly used insulin sensitizer drugs and PPAR gamma activators, thiazolidinediones, act, and which of their physiological effects are dependent of PPAR gamma. It is now evident that the full activation of PPAR gamma is less advantageous than targeted modulation of its activity. Furthermore, new roles for PPAR gamma signaling have been discovered in inflammation, bone morphogenesis, endothelial function, cancer, longevity, and atherosclerosis, to mention a few. Here we draw together and discuss these recent advances in the research into PPAR gamma biology. (c) 2007 Elsevier B.V All rights reserved.
引用
收藏
页码:999 / 1013
页数:15
相关论文
共 157 条
[1]   Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease [J].
Adachi, M. ;
Kurotani, R. ;
Morimura, K. ;
Shah, Y. ;
Sanford, M. ;
Madison, B. B. ;
Gumucio, D. L. ;
Marin, H. E. ;
Peters, J. M. ;
Young, H. A. ;
Gonzalez, F. J. .
GUT, 2006, 55 (08) :1104-1113
[2]   A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy [J].
Agarwal, AK ;
Garg, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :408-411
[3]   Tyrosine Agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ [J].
Agostini, M ;
Gurnell, M ;
Savage, DB ;
Wood, EM ;
Smith, AG ;
Rajanayagam, O ;
Garnes, KT ;
Levinson, SH ;
Xu, HE ;
Schwabe, JWR ;
Willson, TM ;
O'Rahilly, S ;
Chatterjee, VK .
ENDOCRINOLOGY, 2004, 145 (04) :1527-1538
[4]   Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance [J].
Agostini, Maura ;
Schoenmakers, Erik ;
Mitchell, Catherine ;
Szatmari, Istvan ;
Savage, David ;
Smith, Aaron ;
Rajanayagam, Odelia ;
Semple, Robert ;
Luan, Jian'an ;
Bath, Louise ;
Zalin, Anthony ;
Labib, Mourad ;
Kumar, Sudhesh ;
Simpson, Helen ;
Blom, Dirk ;
Marais, David ;
Schwabe, John ;
Barroso, Ines ;
Trembath, Richard ;
Wareham, Nicholas ;
Nagy, Laszlo ;
Gurnell, Mark ;
O'Rahilly, Stephen ;
Chatterjee, Krishna .
CELL METABOLISM, 2006, 4 (04) :303-311
[5]   Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux [J].
Akiyama, TE ;
Sakai, S ;
Lambert, G ;
Nicol, CJ ;
Matsusue, K ;
Pimprale, S ;
Lee, YH ;
Ricote, M ;
Glass, CK ;
Brewer, HB ;
Gonzalez, FJ .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) :2607-2619
[6]   PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors [J].
Akune, T ;
Ohba, S ;
Kamekura, S ;
Yamaguchi, M ;
Chung, UI ;
Kubota, N ;
Terauchi, Y ;
Harada, Y ;
Azuma, Y ;
Nakamura, K ;
Kadowaki, T ;
Kawaguchi, H .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :846-855
[7]   A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy [J].
Al-Shali, K ;
Cao, HN ;
Knoers, N ;
Hermus, AR ;
Tack, CJ ;
Hegele, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (11) :5655-5660
[8]   Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis [J].
Al-Shali, KZ ;
House, AA ;
Hanley, AJG ;
Khan, HMR ;
Harris, SB ;
Zinman, B ;
Mamakeesick, M ;
Fenster, A ;
Spence, JD ;
Hegele, RA .
STROKE, 2004, 35 (09) :2036-2040
[9]   Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation [J].
Ali, AA ;
Weinstein, RS ;
Stewart, SA ;
Parfitt, AM ;
Manolagas, SC ;
Jilka, RL .
ENDOCRINOLOGY, 2005, 146 (03) :1226-1235
[10]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80